This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ImmunoCellular Therapeutics Announces Initiation Of Phase I Trial Of Cancer Vaccine ICT-121 In Recurrent Glioblastoma

ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced initiation of a phase I clinical trial of cancer vaccine ICT-121 as a potential treatment for patients with recurrent glioblastoma multiforme (GBM). The investigator-sponsored phase I trial is being conducted at Cedars-Sinai Medical Center in Los Angeles, CA, by Jeremy Rudnick, MD, and ImmunoCellular is supporting the trial by providing the ICT-121 vaccine. ICT-121 is a dendritic cell vaccine targeting CD133, an important cancer stem cell marker that is commonly overexpressed on a broad range of solid tumors.

The primary objective of the open label phase I trial is to assess the safety and tolerability of ICT-121. Secondary objectives include overall survival (OS) and progression-free survival (PFS) at six months after surgery as well as other response parameters. Approximately 20 patients who have had gross tumor resection and experience a first recurrence of GBM, and who are HLA-A2 positive, will be treated in the trial. Patients will be administered the vaccine once per week for four weeks during the induction phase, followed by a maintenance phase consisting of one treatment every two months until their supply of vaccine is depleted or they experience progressive disease.

“The initiation of the ICT-121 trial completes another important clinical milestone for ImmunoCellular and adds to the substantial pipeline progress we have made this year in advancing our ICT-107 phase II program in patients with newly diagnosed brain cancer,” said Andrew Gengos, ImmunoCellular Chief Executive Officer. “We are positioning our company as an emerging leader in cancer immunotherapy by building our dendritic cell-based vaccine pipeline, maintaining a strong financial underpinning, and planning for the future should we achieve success in our ongoing ICT-107 phase II trial. The second half of 2013 will be an exciting time as we expect to reach the prescribed event level in the ICT-107 trial that triggers analysis of the final results.”

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,780.97 -17.52 -0.10%
S&P 500 2,088.59 -1.52 -0.07%
NASDAQ 5,119.2540 -8.2710 -0.16%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs